Tevogen Advances Strategic Growth with Planned Evaluation of Sciometrix Acquisition

February 26, 2026 – Tevogen today announced that it has signed a Letter of Intent (LOI) to evaluate the potential acquisition of Sciometrix, along with its innovative digital care management platform, Clinicus. The proposed transaction reflects Tevogen’s commitment to expanding its technology-driven healthcare ecosystem and strengthening its ability to deliver integrated, patient-centered solutions at scale.

The evaluation marks a significant step in Tevogen’s long-term strategic plan to blend biotechnology innovation with advanced digital infrastructure. By exploring the acquisition of Sciometrix, Tevogen aims to enhance care coordination, improve clinical outcomes, and create measurable value for patients, providers, and partners.

Strategic Intent Behind the Letter of Intent

The signing of the LOI signals Tevogen’s serious interest in assessing how Sciometrix’s digital capabilities align with its broader mission. While the agreement is non-binding and subject to due diligence, it establishes a framework for both companies to explore synergies, operational integration, and long-term growth potential.

Aligning Digital Infrastructure with Biotech Innovation

Tevogen has built its reputation on innovation in biotechnology and precision medicine. However, modern healthcare increasingly demands seamless digital integration. By evaluating Sciometrix’s Clinicus platform, Tevogen seeks to create a unified ecosystem where therapeutic development and patient management operate in harmony.

Clinicus is designed to support comprehensive care management through data-driven insights, workflow optimization, and coordinated communication among healthcare providers. Integrating such capabilities could significantly enhance Tevogen’s ability to manage patient journeys beyond treatment development.

Enhancing Operational Efficiency

Healthcare systems worldwide face rising costs, regulatory complexity, and increasing patient expectations. A digital care management platform like Clinicus may provide tools to streamline administrative processes, reduce redundancies, and improve decision-making accuracy. Tevogen’s leadership believes that operational efficiency is a key pillar in delivering sustainable healthcare innovation.

About Sciometrix and the Clinicus Platform

Sciometrix is recognized for its technology-driven approach to care coordination. Its flagship platform, Clinicus, focuses on digital care management solutions tailored to complex patient populations and multi-specialty networks.

Core Features of Clinicus

Clinicus is engineered to centralize patient data, enhance communication, and deliver actionable analytics. Key features include:

• Integrated Patient Records: Consolidation of clinical data from multiple sources into a unified digital profile.
• Care Coordination Tools: Real-time collaboration capabilities among physicians, nurses, and care teams.
• Advanced Analytics: Predictive modeling and performance tracking to improve treatment adherence and outcomes.
• Compliance Support: Built-in regulatory safeguards and reporting tools.

These capabilities align with industry demands for technology that not only collects data but also transforms it into meaningful insights.

Focus on Value-Based Care

The healthcare landscape continues to shift toward value-based care models, where providers are rewarded for patient outcomes rather than service volume. Clinicus supports this transition by offering tools that track performance metrics, manage population health, and identify risk factors early in the treatment cycle.

For Tevogen, acquiring such infrastructure could enhance its ability to demonstrate clinical value and optimize patient engagement strategies.

Tevogen’s Vision for Integrated Healthcare

Tevogen has consistently emphasized its mission to deliver accessible, scalable, and science-driven healthcare solutions. The evaluation of Sciometrix fits squarely within this framework.

Bridging Therapeutics and Digital Care

Modern healthcare no longer operates in silos. Drug development, clinical monitoring, patient adherence, and data analytics must function cohesively. Tevogen envisions a future where its therapeutic innovations are supported by a digital backbone that ensures efficient deployment and follow-up care.

By potentially integrating Clinicus, Tevogen could create a closed-loop system in which clinical insights inform treatment strategies in real time. This approach may accelerate innovation while maintaining patient safety and regulatory compliance.

Expanding Market Reach

The potential acquisition also presents an opportunity for geographic and market expansion. Sciometrix’s established client relationships and digital footprint could complement Tevogen’s existing network, opening pathways to new partnerships and healthcare systems.

Through strategic alignment, Tevogen may be able to extend its solutions into underserved markets and enhance global accessibility to advanced care management tools.

Due Diligence and Transaction Process

As outlined in the Letter of Intent, the next phase involves comprehensive due diligence. This process will evaluate financial performance, technological compatibility, intellectual property assets, regulatory considerations, and cultural alignment.

Financial and Operational Review

Tevogen’s financial advisors and internal teams will conduct an in-depth review of Sciometrix’s revenue streams, cost structure, and growth projections. This analysis ensures that any potential transaction supports sustainable value creation for stakeholders.

Technology Assessment

Technical teams from both organizations will assess interoperability, cybersecurity standards, scalability, and system architecture. Ensuring seamless integration is critical to realizing the anticipated benefits of combining therapeutic innovation with digital care management.

Regulatory Considerations

Healthcare technology acquisitions require strict adherence to data privacy laws, patient confidentiality standards, and international compliance regulations. Tevogen is committed to maintaining the highest ethical and regulatory standards throughout the evaluation process.

Leadership Perspectives

Company executives have expressed optimism regarding the potential strategic fit between Tevogen and Sciometrix. Leadership emphasizes that the evaluation is driven by a shared vision of leveraging innovation to improve patient outcomes.

Commitment to Patients and Providers

Tevogen’s management reiterated that any acquisition decision will prioritize patient benefit, clinical integrity, and operational excellence. The goal is not simply expansion but meaningful transformation in how care is delivered and managed.

Long-Term Shareholder Value

From a corporate governance perspective, the potential acquisition aligns with Tevogen’s responsibility to generate long-term shareholder value. Strategic investments in digital infrastructure can position the company competitively within a rapidly evolving healthcare landscape.

Industry Context and Market Trends

The digital health sector has experienced significant growth over the past decade. Advances in cloud computing, artificial intelligence, and data analytics have reshaped how healthcare providers manage patient care.

Rise of Digital Care Management Platforms

Platforms like Clinicus represent a new generation of healthcare technology designed to address fragmentation in patient management. By consolidating data and enhancing communication, such platforms reduce inefficiencies and improve continuity of care.

Increased Demand for Data-Driven Healthcare

Healthcare stakeholders increasingly rely on data analytics to guide decision-making. Predictive modeling, real-time reporting, and risk stratification are becoming essential tools for improving outcomes and controlling costs.

Tevogen’s potential acquisition aligns with this broader industry trend toward digitization and integration.

Potential Impact on Stakeholders

Patients

Patients may benefit from improved care coordination, personalized treatment plans, and more efficient communication between providers. Enhanced digital infrastructure can lead to faster response times and reduced administrative barriers.

Healthcare Providers

Providers could experience streamlined workflows, improved data accessibility, and enhanced collaboration tools. These improvements may reduce burnout and allow clinicians to focus more on patient care.

Investors

Investors may view the evaluation as a forward-thinking move that strengthens Tevogen’s competitive positioning. Diversifying capabilities through digital health integration may create new revenue streams and operational efficiencies.

Forward-Looking Statements and Risk Factors

This announcement includes forward-looking statements regarding the potential acquisition and its anticipated benefits. Such statements are subject to risks and uncertainties, including the successful completion of due diligence, regulatory approvals, market conditions, and integration challenges.

There can be no assurance that a definitive agreement will be executed or that the transaction will be completed. Tevogen remains committed to transparency and will provide updates as appropriate.

Conclusion

The signing of the Letter of Intent to evaluate the potential acquisition of Sciometrix and its Clinicus platform represents a strategic milestone for Tevogen. By exploring the integration of advanced digital care management tools with its biotechnology innovations, Tevogen is positioning itself at the forefront of modern healthcare transformation.

If successfully completed, the acquisition could strengthen Tevogen’s capacity to deliver comprehensive, technology-enabled healthcare solutions that prioritize efficiency, accessibility, and improved patient outcomes. As the evaluation progresses, stakeholders will closely monitor developments that may shape the company’s next phase of growth.

Through disciplined analysis, strategic foresight, and a commitment to excellence, Tevogen continues to demonstrate leadership in navigating the evolving healthcare landscape. The potential collaboration with Sciometrix underscores a shared vision: harnessing innovation to create a smarter, more connected future for healthcare worldwide.

#SlimScan #GrowthStocks #CANSLIM